Now, however, concerns over these drugs’ safety and side effects in children and adolescents – including elevated suicide rates – have awakened regulators in many countries. After reviewing all relevant pediatric trials, the UK’s Medinces and Heathcare products Regulatory Agency (MHRA) advised that the risks outweighed the benefits for all SSRI’s (except fluoxetine), and that these products should not be prescribed as new therapy for patients under 18 years of age with depressive illness.
但是现在，这些药品对儿童和青少年的安全性问题及其副作用——其中包括不断上升的自杀率——已经引起了许多国家政府的重视。在评估了所有相关儿科案例之后，英国医药与健康产品管理委员会(MHRA)认为所有的SSRI’s药物的（除了氟西汀以外）风险性大于其药效，因此禁止将这些药品作为治疗18岁以下患者的治疗用药。